Alaunos Therapeutics (TCRT) Competitors $1.96 -0.06 (-2.97%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TCRT vs. KZIA, TLPH, SNSE, TSBX, KPRX, JAGX, PHXM, CLRB, INDP, and EGRXShould you be buying Alaunos Therapeutics stock or one of its competitors? The main competitors of Alaunos Therapeutics include Kazia Therapeutics (KZIA), Talphera (TLPH), Sensei Biotherapeutics (SNSE), Turnstone Biologics (TSBX), Kiora Pharmaceuticals (KPRX), Jaguar Health (JAGX), PHAXIAM Therapeutics (PHXM), Cellectar Biosciences (CLRB), Indaptus Therapeutics (INDP), and Eagle Pharmaceuticals (EGRX). These companies are all part of the "pharmaceutical products" industry. Alaunos Therapeutics vs. Kazia Therapeutics Talphera Sensei Biotherapeutics Turnstone Biologics Kiora Pharmaceuticals Jaguar Health PHAXIAM Therapeutics Cellectar Biosciences Indaptus Therapeutics Eagle Pharmaceuticals Alaunos Therapeutics (NASDAQ:TCRT) and Kazia Therapeutics (NASDAQ:KZIA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, community ranking, media sentiment and analyst recommendations. Does the MarketBeat Community prefer TCRT or KZIA? Kazia Therapeutics received 72 more outperform votes than Alaunos Therapeutics when rated by MarketBeat users. However, 58.33% of users gave Alaunos Therapeutics an outperform vote while only 52.67% of users gave Kazia Therapeutics an outperform vote. CompanyUnderperformOutperformAlaunos TherapeuticsOutperform Votes758.33% Underperform Votes541.67% Kazia TherapeuticsOutperform Votes7952.67% Underperform Votes7147.33% Is TCRT or KZIA more profitable? Kazia Therapeutics' return on equity of 0.00% beat Alaunos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Alaunos TherapeuticsN/A -267.77% -209.18% Kazia Therapeutics N/A N/A N/A Do analysts recommend TCRT or KZIA? Kazia Therapeutics has a consensus target price of $20.00, suggesting a potential upside of 562.25%. Given Kazia Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Kazia Therapeutics is more favorable than Alaunos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alaunos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Kazia Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor TCRT or KZIA? In the previous week, Alaunos Therapeutics' average media sentiment score of 0.00 equaled Kazia Therapeutics'average media sentiment score. Company Overall Sentiment Alaunos Therapeutics Neutral Kazia Therapeutics Neutral Do insiders and institutionals have more ownership in TCRT or KZIA? 27.7% of Alaunos Therapeutics shares are owned by institutional investors. Comparatively, 30.9% of Kazia Therapeutics shares are owned by institutional investors. 5.1% of Alaunos Therapeutics shares are owned by company insiders. Comparatively, 1.0% of Kazia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has preferable earnings & valuation, TCRT or KZIA? Kazia Therapeutics has higher revenue and earnings than Alaunos Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlaunos Therapeutics$7K448.28-$35.14MN/AN/AKazia Therapeutics$2.31M5.70-$17.56MN/AN/A Which has more risk and volatility, TCRT or KZIA? Alaunos Therapeutics has a beta of -0.45, indicating that its stock price is 145% less volatile than the S&P 500. Comparatively, Kazia Therapeutics has a beta of 1.98, indicating that its stock price is 98% more volatile than the S&P 500. SummaryKazia Therapeutics beats Alaunos Therapeutics on 10 of the 13 factors compared between the two stocks. Ad InvestorPlaceWall Street Icon: “You must get on the right side of this thing”I created one of the first quantitative analysis-based stock picking systems long before "quants" became a thing on Wall Street… leading Forbes to call me "King of the Quants." I'm writing to you today because my system has recently uncovered a market phenomenon I haven't seen in 30 years.This market shakeup is going to be much more intense. Get Alaunos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TCRT vs. The Competition Export to ExcelMetricAlaunos TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.14M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E RatioN/A10.5990.0517.20Price / Sales448.28196.061,117.09117.04Price / CashN/A57.1643.1037.85Price / Book0.505.094.784.78Net Income-$35.14M$151.83M$120.31M$225.60M7 Day Performance3.16%-2.14%-1.92%-1.23%1 Month Performance-17.99%-4.56%13.65%0.46%1 Year Performance-73.60%8.87%28.34%15.24% Alaunos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TCRTAlaunos TherapeuticsN/A$1.96-3.0%N/A-73.1%$3.14M$7,000.000.0040KZIAKazia Therapeutics1.7318 of 5 stars$3.42-3.7%$20.00+484.8%-21.6%$11.39M$2.31M0.0012Gap UpTLPHTalphera2.886 of 5 stars$0.67+2.8%$4.50+573.1%N/A$11.38M$281,000.00-0.9419Positive NewsSNSESensei Biotherapeutics4.0699 of 5 stars$0.44+0.2%$4.33+883.1%-28.6%$11.09MN/A-0.3740TSBXTurnstone Biologics2.849 of 5 stars$0.48-0.9%$2.13+346.8%-80.2%$11.00M$19.31M-0.1582KPRXKiora Pharmaceuticals2.1064 of 5 stars$3.64+9.6%$10.00+174.7%-32.5%$10.92M$16M0.0010Positive NewsGap UpJAGXJaguar Health0.2597 of 5 stars$0.91-6.4%N/A-89.9%$10.70M$9.76M0.0050News CoverageGap UpPHXMPHAXIAM TherapeuticsN/A$3.10-0.6%N/AN/A$10.58M$32.66M0.0049CLRBCellectar Biosciences1.7974 of 5 stars$0.25-5.7%$17.67+7,102.1%-91.1%$10.12MN/A-0.1510Analyst ForecastGap UpHigh Trading VolumeINDPIndaptus Therapeutics2.868 of 5 stars$0.98-2.0%$8.50+767.3%-49.6%$9.99MN/A-0.586EGRXEagle Pharmaceuticals1.004 of 5 stars$0.75+36.4%N/A-89.0%$9.74M$257.55M0.00134Gap Down Related Companies and Tools Related Companies Kazia Therapeutics Alternatives Talphera Alternatives Sensei Biotherapeutics Alternatives Turnstone Biologics Alternatives Kiora Pharmaceuticals Alternatives Jaguar Health Alternatives PHAXIAM Therapeutics Alternatives Cellectar Biosciences Alternatives Indaptus Therapeutics Alternatives Eagle Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TCRT) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alaunos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alaunos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TCRT Stock Alerts